# Development of a SARS-CoV-2 vaccine for the elderly by engineering virus-like particles with SARS-CoV-2 antigen and membrane-anchored cytokines

> **NIH NIH N44** · METACLIPSE THERAPEUTICS CORPORATION · 2020 · $2,199,976

## Abstract

Vaccine design using SARS-CoV-2 spike protein on VLPs which contain GM-CSF and IL-12 (targeting elderly).  There is data supporting the premise that including GM-CSF and IL-12 in the VLP can overcome poor immune responses in elderly.  
Animal testing will begin  using VLP with antigen and cytokines, this process will be optimized for GMP and scale-up.

## Key facts

- **NIH application ID:** 10259987
- **Project number:** 75N93019C00017-P00003-9999-2
- **Recipient organization:** METACLIPSE THERAPEUTICS CORPORATION
- **Principal Investigator:** CHRISTOPHER PACK
- **Activity code:** N44 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $2,199,976
- **Award type:** —
- **Project period:** 2019-08-16 → 2022-08-15

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10259987

## Citation

> US National Institutes of Health, RePORTER application 10259987, Development of a SARS-CoV-2 vaccine for the elderly by engineering virus-like particles with SARS-CoV-2 antigen and membrane-anchored cytokines (75N93019C00017-P00003-9999-2). Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/grant/nih/10259987. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*